Nitroflurbiprofen (NicOx).
Nitroflurbiprofen is a nitrosylated flurbiprofen analog under development by NicOx for the potential treatment of urinary incontinence, Alzheimer's disease (AD) and the prevention and treatment of accelerated bone resorption associated with disorders such as osteoporosis, inflammatory joint disease and Paget's disease. In addition, a topical formulation of nitroflurbiprofen is under development for the potential treatment of dermatological disorders, including contact urticaria. By 1999, nitroflurbiprofen was in phase IIa trials for urinary incontinence, Paget's disease and osteoporosis, and phase II trials of the topical formulation were underway in contact urticaria by March 2002. Phase I trials for AD had commenced by May 2003, and in September 2003, NicOx was intending to conduct further phase II trials for micturition disorders in 2003.
Scatena
Roberto
R
Istituto di Biochimica e Biochimica Clinica, Faculty of Medicine, Universita' Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy. r.scatena@uniserv.ccr.rm.cnr.it
D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D001168:Arthritis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005480:Flurbiprofen / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D020030:Nitric Oxide Donors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010001:Osteitis Deformans / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy; D013329:Structure-Activity Relationship; D014549:Urinary Incontinence / Q000188:drug therapy; D014581:Urticaria / Q000188:drug therapy
D016861:Cyclooxygenase Inhibitors; D020030:Nitric Oxide Donors; C095631:nitroflurbiprofen; D005480:Flurbiprofen